As such reports are scarce, the aim of this study was to investigate the impact of pharmacological intervention for EGFR mutations in early-stage lung cancer on recurrence and prognosis in patients with NSCLC in order to find strong scientific evidence to support clinical decision-making. Here, EGFR is linked to lung carcinoma.